(Gastric Cancer) Is Enhertu Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 24, 2022
- Reading time: 1 minute
On November 15, 2022, Kensei Yamaguchi and colleagues from Cancer Institute Hospital published results in the Journal of Clinical Oncology from the DESTINY-Gastric01 Phase II clinical trial evaluating Enhertu (trastuzumab deruxtecan) in HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer patients with two or more prior lines of therapy.
The DESTINY-Gastric01 Phase II trial was a multicenter open-label study that randomized HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy in a 2:1 ratio to the Enhertu arm (6.4 mg/kg every 3 weeks) or chemotherapy arm. Primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate, progression-free survival (PFS), and overall survival (OS). Patients were classified into cohort 1 (N=21) and cohort 2 (N=24) based on HER2 classification.
Results:
ORR: cohort 1 26.3% / cohort 2 9.5%. Tumor shrinkage rate: cohort 1 68.4% (N=13) / cohort 2 60.0% (N=12).
Median OS: cohort 1 7.8 months / cohort 2 8.5 months. Median PFS: cohort 1 4.4 months / cohort 2 2.8 months.
Safety:
Grade ≥3 adverse events included anemia (cohort 1: 30.0% / cohort 2: 29.2%), neutropenia (cohort 1: 25.0% / cohort 2: 29.2%), and decreased appetite (cohort 1: 20.0% / cohort 2: 20.8%). Drug-induced interstitial lung disease was confirmed in one patient per cohort.
Based on the DESTINY-Gastric01 trial results, Kensei Yamaguchi and colleagues concluded that Enhertu demonstrated clinically meaningful antitumor activity in HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00575
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4